SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2002

MoliChem Medicines, Inc.

(Exact name of Company as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

333-64430		330820923
(Commission file Number)		(IRS Employer ID Number)

100 Europa Drive, Suite 421, Chapel Hill, North Carolina		27517-2389
(Address of principal executive offices)		(Zip Code)

919-960-0217

Company’s telephone number, including area code

Item 5. Other Events and Regulation D Disclosure.

On November 12, 2002, MoliChem issued a press release. A copy of the press release is being furnished as Exhibit 99.1 MoliChem regards any information provided in the press release to be current and accurate only as of the date of the press release and specifically disclaims any duty to update such information unless it is necessary to do so in accordance with applicable law.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

Exhibit No.		Description

99.1		Press Release, dated November 12, 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		MOLICHEM MEDICINES, INC.

Date: November 12, 2002		/s/ LUIS MOLINA
		Luis Molina, Ph.D.,
		Chief Executive Officer

INDEX TO EXHIBITS

Exhibit No.		Description

99.1		Press Release, dated November 12, 2002

MOLICHEM MEDICINES INC 8-K